Chemotherapy of Metastatic Carcinoma of the Breast

References

• Ahmann D. L., Eagan R. T., Bisel H. F., Hahn R. G., O'Connell M. J., Edmonson J. H. Evaluation of combination therapy with adriamycin (NSC-123127) and metho-trexate (NSC-740) in patients with disseminating breast cancer. Cancer Chemother. Rep. 1975; 6: 335
   Google Scholar
• Baum M. The curability of breast cancer. Brit. med. J. 1976; 1: 439
   PubMed Web of Science ®Google Scholar
• Benjamin R. S. Clinical pharmacology of adriamycin (NSC-123127). Cancer Chemother. Rep. 1975; 6: 183
   Google Scholar
• Blumenschein R., Cardenas J., Freireich E., Gottlieb J. FAC chemotherapy for breast cancer. Proc. Amer. Soc. clin. Oncol. 1974; 15: 15, (abstr.)
   Google Scholar
• Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brugnatelli L., Brambilla C., De Lena M., Tancini G., Bajetta E., Musumeci R., Veronesi U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. New Engl. J. Med. 1976; 294: 405
   PubMed Web of Science ®Google Scholar
• Brown I., Ward H. W. C. Doxorubicin in the treatment of advanced breast cancer: comparative studies of three combination chemotherapy regimes. Clin. Oncol. 1976; 2: 105
   PubMedGoogle Scholar
• Canellos G. P., De Vita V. T., Gold L. G., Shabner B. A., Schein P. S., Young R. C. Cyclical combination chemotherapy for advanced breast carcinomas. Brit. med. J. 1974; 218
   PubMed Web of Science ®Google Scholar
• Carter S. K. Single and combination nonhormonal chemotherapy in breast cancer. Cancer 1972; 30: 1543
   PubMed Web of Science ®Google Scholar
• Carter S. K. Some thoughts on experimental models and their clinical correlations. Europ. J. Cancer 1973; 9: 833
   Web of Science ®Google Scholar
• Carter S. K. Adriamycin a review. J. nat. Cancer Inst. 1975; 35: 1265
   Google Scholar
• Cooper R. Combination chemotherapy in hormone resistent breast cancer. Proc. Amer. Ass. Cancer Res. 1969; 10: 15, (abstr.)
   Web of Science ®Google Scholar
• Corbett T. H., Griswold D. P., Mayo J. G., Laster W. R., Schabel F. M., Jr. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors. Cancer Res. 1975; 35: 1568
   PubMed Web of Science ®Google Scholar
• Creech R. H., Catalano R. B., Mastralgilo M. J., Engstrom P. F. An effective low-dose intermittent cyclophosphamide, methotrexate, 5-fluorouracil treatment regime for metastatic breast cancer. Cancer 1975; 35: 1101
   PubMed Web of Science ®Google Scholar
• De Lena M., Brambilla C., Morabito A., Bonadonna G. Adriamycin plus Vincristine compared to and combined with cyclophosphamide, methotrexate and 5-fluorouracil for advanced breast cancer. Cancer 1975; 35: 1108
   PubMed Web of Science ®Google Scholar
• De Vita V. T., Jr., Young R. C., Canellos G. P. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975; 35: 98
   PubMed Web of Science ®Google Scholar
• Eagan R. T., Ahmann D. L., Edmonson J. H., Hahn R. G., Bisel H. F. Controlled evaluation of combination of adriamycin (NSC-123127), vincristine (NSC-67574), and methotrexate (NSC-740) in patients with disseminated breast cancer. Cancer Chemother. Rep. 1975; 6: 339
   Google Scholar
• Fisher B., Slack N. H., Bross I. D. J. Cancer of the breast— size of neoplasm and prognosis. Cancer 1969; 24: 1071
   PubMed Web of Science ®Google Scholar
• Greenspan E. N. Combination cytotoxic chemotherapy in advanced disseminated breast cancer. J. Mt Sinai Hosp. 1966; 33: 1
   PubMedGoogle Scholar
• Hill B. T., Price L. A., Goldie J. H. The value of adriamycin in overcoming resistance to methotrexate in tissue culture. Europ. J. Cancer 1976; 12: 541
   Web of Science ®Google Scholar
• Jones S. E., Durie B. G. M., Salmon S. E. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 1975; 36: 90
   PubMed Web of Science ®Google Scholar
• Sartorelli A. C. Some approaches to the therapeutic exploitation of metabolic sites of vulnerability of neoplastic cells. Cancer Res. 1969; 29: 2292
   PubMed Web of Science ®Google Scholar
• Silvestrini R., Sanfilippo O., Tedesco G. Kinetics of human mammary carcinomas and their correlation with the cancer and the host characteristics. Cancer 1974; 34: 1252
   PubMed Web of Science ®Google Scholar
• Skipper H. E. Kinetics of tumor cell growth and implications for therapy. Cancer 1971; 28: 1479
   PubMed Web of Science ®Google Scholar
• Taylor S. G., III, Canellos G. P., Band P., Pocock S. Combination chemotherapy for advanced breast cancer— randomized comparison with single drug therapy. Proc. Amer. Soc. clin. Oncol. 1974; 15: 1975, (abstr.)
   Google Scholar
• Tormey D. C. Adriamycin (NSC-123147) in breast cancer: an overview of studies. Cancer Chemother. 1975; 6: 319
   Google Scholar
• Van Putten L. M., Keizer H. J., Mulder J. H. Perspectives in cancer research. Synchronization in tumor chemotherapy. Europ. J. Cancer 1976; 12: 79
   Web of Science ®Google Scholar
• Wasserman T. H., Comis R. L., Goldsmith G., Handelsman H., Penta J. S., Slavik M., Soper W. T., Carter S. K. Tabular analyses of the clinical chemotherapy of solid tumors. Cancer Chemother. Rep. 1975; 3: 399
   Google Scholar